Molecular Phenotypes for Lung Diseases (R01)

The summary for the Molecular Phenotypes for Lung Diseases (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Molecular Phenotypes for Lung Diseases (R01): -Purpose. The National Heart, Lung, and Blood Institute (NHLBI) solicits grant applications under this Funding Opportunity Announcement (FOA) to stimulate research that will define or subcategorize human lung diseases at a molecular level enabling early diagnosis, prognosis, and personalized treatment of these diseases. The measurement of whole-genome gene expression at the RNA level will be the primary approach to systematically collect molecular phenotyping data for common and rare lung diseases. In addition, this FOA encourages the integration of data from other omics approaches (e.g., genomics, epigenomics, etc.) to reinforce or validate findings from RNA expression. The data generated from this program will be made available to the broad scientific community. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. Contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications, the total amount of $16 million will be used to fund up to 6 awards of 4 years duration.

Federal Grant Title:	Molecular Phenotypes for Lung Diseases (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-08-006
Type of Funding:	Grant
CFDA Numbers:	93.838
CFDA Descriptions:	Lung Diseases Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	May 05, 2008
Posted Date:	Feb 21, 2008
Creation Date:	Feb 21, 2008
Archive Date:	Jun 05, 2008
Total Program Funding:	$16,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification) Private institutions of higher education City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Special district governments Public and State controlled institutions of higher education County governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses Public housing authorities/Indian housing authorities Independent school districts
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Limited Competition: Physician Scientist Transition to Independence in Blood Science Resea...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordi...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissu...; • Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clin...; • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models; • Lung Response to Inhaled Highly Toxic Chemicals; • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...